Piper Sandler analyst Biren Amin assumed coverage of Lenz Therapeutics (LENZ) with an Overweight rating with a price target of $51, up from $38, on the potential of LNZ100, an acelidine-based topical eyedrop for presbyopia, which affects about 128M individuals in the U.S. With the NDA accepted last October and a PDUFA assigned for August 8, 2025, LNZ100 is on track to launch in Q4 2025. The firm believes LNZ100 has a best-in-indication profile, superior to AbbVie’s (ABBV) Vuity and Tenpoint’s Bramichol. Piper’s model estimates U.S. sales of $58M in 2026, growing to $592M by 2035.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- new option listings on April 9th
- Lenz Therapeutics files to sell 13.07M shares of common stock for holders
- Lenz Therapeutics files $500M mixed securities shelf
- Lenz Therapeutics’ Earnings Call Highlights Positive Outlook
- Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid Strong Market Position and Upcoming Product Launch